Docetaxel versus paclitaxel for antiangiogenesis

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• Cytotoxic chemotherapy agents like paclitaxel possess antiangiogenic properties.
• Angiogenesis is crucial for tumor growth and metastasis.
• Understanding the antiangiogenic mechanisms of chemotherapy is vital for developing novel cancer therapies.

Purpose of the Study:

• To compare the antiangiogenic activity of docetaxel and paclitaxel.
• To determine the non-cytotoxic doses of docetaxel and paclitaxel with antiangiogenic effects.
• To investigate the in vitro and in vivo effects of these agents on endothelial cells and angiogenesis.

Main Methods:

• In vitro assessment of human endothelial cell functions (proliferation, chemotaxis, morphogenesis, protease secretion) exposed to docetaxel and paclitaxel.
• In vivo antiangiogenesis assay using the chick embryo chorioallantoic membrane (CAM) model.
• Evaluation of cytotoxicity and apoptosis induction in various cancer cell lines and fibroblasts.

Main Results:

• Non-cytotoxic doses of docetaxel (0.5-1 nM) and paclitaxel (2-4 nM) impaired endothelial cell functions in a dose-dependent manner.
• These low doses did not significantly affect the proliferation of most tested tumor cells, except Kaposi's sarcoma.
• In vivo studies confirmed dose-dependent antiangiogenic activity for both drugs, with docetaxel demonstrating higher potency.

Conclusions:

• Very low doses of docetaxel and paclitaxel selectively induce functional and structural damage to endothelial cells.
• Docetaxel exhibits approximately four times the antiangiogenic potency of paclitaxel.
• The antiangiogenic effects of these agents at low doses may offer therapeutic potential for Kaposi's sarcoma and other cancers.